cefixime has been researched along with Haemophilus Infections in 13 studies
Cefixime: A third-generation cephalosporin antibiotic that is stable to hydrolysis by beta-lactamases.
cefixime : A third-generation cephalosporin antibiotic bearing vinyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is used in the treatment of gonorrhoea, tonsilitis, pharyngitis, bronchitis, and urinary tract infections.
Haemophilus Infections: Infections with bacteria of the genus HAEMOPHILUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with purulent exacerbation of chronic bronchitis were randomized to receive either a single 400-mg daily dose of cefixime or 250 mg of cephalexin, orally, four times a day." | 9.06 | Randomized comparative study of cefixime versus cephalexin in acute bacterial exacerbations of chronic bronchitis. ( Kalbfleisch, JH; Roberson, D; Sarubbi, F; Verghese, A, 1990) |
| " The antibiotic was given at a dosage of 200 mg b." | 6.67 | [Clinical experiences with cefixime in the treatment of bacterial infections of the lower respiratory tract]. ( Kersten, W; Müsken, H, 1990) |
| "Patients with purulent exacerbation of chronic bronchitis were randomized to receive either a single 400-mg daily dose of cefixime or 250 mg of cephalexin, orally, four times a day." | 5.06 | Randomized comparative study of cefixime versus cephalexin in acute bacterial exacerbations of chronic bronchitis. ( Kalbfleisch, JH; Roberson, D; Sarubbi, F; Verghese, A, 1990) |
| " Using the chinchilla animal model, we compared the efficacy of ceftibuten (n = 33) with that of saline (n = 34), ampicillin (n = 32), and cefixime (n = 31) for the treatment of acute otitis media caused by beta-lactamase-producing nontypeable Hemophilus influenzae." | 3.68 | Efficacy of ceftibuten for acute otitis media caused by Hemophilus influenzae: an animal study. ( Doyle, WJ; Greene, I; Rosenfeld, RM; Seroky, J; Swarts, JD, 1993) |
| " Single doses of each agent were administered and serum concentrations were collected over the standard dosing period of 24 h for all study regimens." | 2.70 | Pharmacodynamics of ceftriaxone and cefixime against community-acquired respiratory tract pathogens. ( Ambrose, PG; Nicolau, DP; Nightingale, CH; Owens, RC; Quintiliani, R; Tessier, P, 2001) |
| " The antibiotic was given at a dosage of 200 mg b." | 2.67 | [Clinical experiences with cefixime in the treatment of bacterial infections of the lower respiratory tract]. ( Kersten, W; Müsken, H, 1990) |
| "6 microg/ml, respectively with 200 or 400 mg doses of cefditoren pivoxil; plasma concentrations exceed 1 microg/ml for 4 to 6 hours (33-50% of dosing interval)." | 1.31 | Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species. ( Beach, ML; Biedenbach, DJ; Johnson, DM; Jones, RN; Pfaller, MA, 2000) |
| "Cefixime was active against the ampicillin-susceptible and ampicillin-resistant, beta-lactamase-producing isolates; however, its activity against some non-beta-lactamase-producing, ampicillin-resistant isolates appeared to be limited." | 1.28 | Comparative in vitro activity of cefixime against Haemophilus influenzae isolates, including ampicillin-resistant, non-beta-lactamase-producing isolates, from pediatric patients. ( Himes, SL; Mortensen, JE, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (30.77) | 18.7374 |
| 1990's | 5 (38.46) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Verhoef, J | 1 |
| Gillissen, A | 1 |
| Doern, GV | 1 |
| Jones, RN | 2 |
| Gerlach, EH | 1 |
| Hindler, J | 1 |
| St Amand, R | 1 |
| Rosenfeld, RM | 1 |
| Doyle, WJ | 2 |
| Swarts, JD | 1 |
| Seroky, J | 1 |
| Greene, I | 1 |
| Johnson, DM | 1 |
| Biedenbach, DJ | 1 |
| Beach, ML | 1 |
| Pfaller, MA | 1 |
| Owens, RC | 1 |
| Tessier, P | 1 |
| Nightingale, CH | 1 |
| Ambrose, PG | 1 |
| Quintiliani, R | 1 |
| Nicolau, DP | 1 |
| Hamilton-Miller, JM | 1 |
| Kersten, W | 1 |
| Müsken, H | 1 |
| Verghese, A | 1 |
| Roberson, D | 1 |
| Kalbfleisch, JH | 1 |
| Sarubbi, F | 1 |
| Mortensen, JE | 1 |
| Himes, SL | 1 |
| Bodor, FF | 1 |
| Kumar, A | 1 |
| Kelly, KJ | 1 |
| Hotaling, AJ | 1 |
| Cantekin, EI | 1 |
| Meguro, H | 1 |
| Arimasu, O | 1 |
| Sohda, H | 1 |
| Yoshida, J | 1 |
| Togasaki, K | 1 |
| Fujii, R | 1 |
2 reviews available for cefixime and Haemophilus Infections
| Article | Year |
|---|---|
Resistant Haemophilus influenzae in community-acquired respiratory tract infections: a role for cefixime.
Topics: Anti-Bacterial Agents; Cefixime; Community-Acquired Infections; Haemophilus Infections; Haemophilus | 2003 |
Overview of cefixime use in community-acquired infections.
Topics: Cefixime; Cephalosporins; Community-Acquired Infections; Escherichia coli Infections; Female; Haemop | 2000 |
3 trials available for cefixime and Haemophilus Infections
| Article | Year |
|---|---|
Pharmacodynamics of ceftriaxone and cefixime against community-acquired respiratory tract pathogens.
Topics: Administration, Oral; Adult; Blood Bactericidal Activity; Cefixime; Ceftriaxone; Cephalosporins; Com | 2001 |
[Clinical experiences with cefixime in the treatment of bacterial infections of the lower respiratory tract].
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Bronchopneu | 1990 |
Randomized comparative study of cefixime versus cephalexin in acute bacterial exacerbations of chronic bronchitis.
Topics: Acute Disease; Bronchitis; Cefixime; Cefotaxime; Cephalexin; Chronic Disease; Gram-Negative Bacteria | 1990 |
8 other studies available for cefixime and Haemophilus Infections
| Article | Year |
|---|---|
Revised disk diffusion interpretive criteria for cefaclor, loracarbef, cefprozil and cefixime when testing Haemophilus influenzae on haemophilus test medium.
Topics: Cefaclor; Cefixime; Cefotaxime; Cefprozil; Cephalosporins; Culture Media; Haemophilus Infections; Ha | 1994 |
Efficacy of ceftibuten for acute otitis media caused by Hemophilus influenzae: an animal study.
Topics: Acute Disease; Ampicillin; Animals; Anti-Bacterial Agents; Cefixime; Cefotaxime; Ceftibuten; Cephalo | 1993 |
Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species.
Topics: Cefaclor; Cefixime; Cephalosporins; Gram-Negative Bacterial Infections; Haemophilus Infections; Haem | 2000 |
Comparative in vitro activity of cefixime against Haemophilus influenzae isolates, including ampicillin-resistant, non-beta-lactamase-producing isolates, from pediatric patients.
Topics: Ampicillin Resistance; beta-Lactamases; Cefixime; Cefotaxime; Ceftriaxone; Haemophilus Infections; H | 1990 |
Systemic antibiotics for treatment of the conjunctivitis-otitis media syndrome.
Topics: Administration, Oral; Ampicillin; Anti-Bacterial Agents; Cefaclor; Cefixime; Cefotaxime; Child; Chil | 1989 |
In vitro activity of cefixime (CL284635) and other antimicrobial agents against Haemophilus isolates from pediatric patients.
Topics: Anti-Bacterial Agents; Cefixime; Cefotaxime; Child; Drug Combinations; Haemophilus Infections; Haemo | 1988 |
Efficacy of a new cephalosporin for acute otitis media.
Topics: Ampicillin; Animals; beta-Lactamases; Cefixime; Cefotaxime; Chinchilla; Haemophilus Infections; Haem | 1987 |
[Clinical evaluation of cefixime in children].
Topics: Bacterial Infections; Cefixime; Cefotaxime; Child; Child, Preschool; Female; Haemophilus Infections; | 1986 |